Vol. 3 No. 1 (2023)
Reimbursement Reviews

Trastuzumab Deruxtecan (Enhertu)

decorative image

Published January 24, 2023

Key Messages

  • CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses trastuzumab deruxtecan (Enhertu) for injection, powder for concentrate for solution for infusion, 100 mg, IV infusion.
  • Indication: For the treatment of adult patients with unresectable or metastatic HER2 (human epidermal growth factor receptor 2)-positive breast cancer who have received at least 1 prior anti-HER2-based regimen either
    • in the metastatic setting, or
    • in the neoadjuvant or adjuvant setting and developed disease recurrence during or within 6 months of completing neoadjuvant or adjuvant therapy.